OR WAIT null SECS
Increases in efficiencies, flexibility, scalability, and sustainability are impacting adoption.
Innovation in this space depends on strategizing for GMP compliance and market access.
Despite a growing trend toward single-use bioreactors, stainless-steel retains its relevance for certain products.
This article explores a grouping strategy for therapeutic peptides incorporating theoretical and experimental methodology and results to define a practical and scientifically justified cleaning procedure.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
March 12, 2024
The Italian company’s North American business has seen an increase of 47%.
March 11, 2024
The Alliance will receive the NSF Regional Innovation Engines Development Award and $1 million in funding.
March 08, 2024
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
The Data Analysis and Real World Interrogation Network, DARWIN EU, is planning to add 10 new data partners in 2024.
March 07, 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.
The agency has published final guidance documents regarding validation and development of analytical procedures.
March 06, 2024
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.
March 04, 2024
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
CPHI North America is a three-day event offering opportunities to learn, innovate, and network in the pharmaceutical industry.
The 6th Treg-Directed Therapies Summit will feature leading industry and academic experts in the Treg therapy field.
March 02, 2024
Despite a growing number of biosimilar approvals, market uptake remains a challenge.